Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
Expert Video - What targeted therapies are used for people with the EGFR mutation?
Erlotinib, gefitinib, and afatinib are commonly used to treat EGFR mutations in non-small-cell lung cancer, according to Robert Winn, MD, director of the Massey Cancer Center at Virginia Commonwealth University. He also discusses second-line drugs, what happens if patients do not respond to targeted therapies, and how biomarker testing for EGFR and other driver mutations can lead to use of additional targeted therapies for lung cancer.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Section: Targeted Therapy in NSCLC
Expert Videos
Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
